2,164
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Bristol Myers Squibb's recently active trials. Comparator arms are excluded.
Upcoming readouts
Next primary completion dates among Bristol Myers Squibb's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Oct 2026A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Al…Phase 3
- Nov 2026BALSAM-1: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipo…Phase 3
- Nov 2026A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipo…Phase 3
- Nov 2026A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEP…Phase 3
- Dec 2026A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Al…Phase 3
- Jan 2027SUCCESSOR-1: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bort…Phase 3
Top therapeutic areas
Conditions studied most often across Bristol Myers Squibb's recently active trials.
- Schizophrenia7 trials
- Alzheimer Disease4 trials
- Alzheimer's Disease4 trials
- Melanoma3 trials
- Plaque Psoriasis3 trials
- Agitation2 trials
Bristol Myers Squibb pipeline by phase
The main study drugs across 218 active trials Bristol Myers Squibb leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 319 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Nivolumab | 10 | 2 | Sept 2026 est. | NCT06561386 · NCT04099251 · NCT04025879 |
| AdagrasibMRTX849 | 8 | 4 | Oct 2026 est. | NCT06875310 · NCT04793958 · NCT04685135 |
| Pumitamig | 7 | 7 | Sept 2028 est. | NCT07361510 · NCT07361497 · NCT07680764 |
| GolcadomideBMS-986369 · CC-99282 | 6 | 1 | Dec 2026 est. | NCT06911502 · NCT06356129 · NCT06425302 |
| BMS-986353CC-97540 | 5 | — | Jul 2027 est. | NCT07335562 · NCT07603557 · NCT07015983 |
| Iza-brenBMS-986507 | 5 | 4 | Mar 2028 est. | NCT07680790 · NCT07106762 · NCT07100080 |
| Repotrectinib | 5 | 3 | Sept 2026 est. | NCT06140836 · NCT04094610 · NCT03093116 |
| MezigdomideCC-92480 | 4 | 2 | Oct 2026 est. | NCT05552976 · NCT05519085 · NCT05372354 |
| Arlocabtagene AutoleucelBMS-986393 | 3 | 3 | Dec 2027 est. | NCT06615479 · NCT06297226 · NCT06121843 |
| BMS-986278 | 3 | — | Oct 2026 est. | NCT07441408 · NCT06025578 · NCT06003426 |
| IberdomideCC-220 | 3 | — | Dec 2028 est. | NCT05827016 · NCT04884035 · NCT02773030 |
| RYZ101 | 3 | 1 | Dec 2026 est. | NCT05477576 · NCT06590857 · NCT05595460 |
| Abatacept | 1 | — | — | NCT04909801 |
| Belatacept | 1 | 1 | Dec 2032 est. | NCT04877288 |
| BMS-986365 | 1 | — | Sept 2027 est. | NCT06764485 |
| BMS-986489 (Atigotatug+Nivolumab) | 1 | 1 | Apr 2028 est. | NCT06646276 |
| idecabtagene vicleucel | 1 | — | — | NCT06045806 |
| Ipilimumab | 1 | — | — | NCT04008030 |
| Nivolumab and rHuPH20 | 1 | — | — | NCT04810078 |
Phase 212 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| NavlimetostatBMS-986504 · MRTX1719 | 10 | 7 | Dec 2026 est. | NCT07492680 · NCT07076121 · NCT07063745 |
| BMS-986368 | 3 | 2 | Feb 2027 est. | NCT06808984 · NCT06782490 · NCT07700329 |
| BMS-986435 | 3 | 2 | Dec 2026 est. | NCT06122779 · NCT07248839 · NCT07226817 |
| Oral AzacitidineCC-486 | 3 | — | Jul 2028 est. | NCT05469737 · NCT05413018 · NCT05197426 |
| BMS-986446 | 2 | — | Mar 2027 est. | NCT06268886 · NCT07780383 |
| Fludarabine | 2 | 1 | Mar 2029 est. | NCT04245839 · NCT07115745 |
| Adagrasib oral dose of 400 mg twice daily tablets | 1 | — | Sept 2026 est. | NCT05609578 |
| BMS-986511 | 1 | — | Nov 2028 est. | NCT07772531 |
| Gene-modified (GM) T cell therapy | 1 | 1 | Nov 2036 est. | NCT03435796 |
| Relatlimab | 1 | — | — | NCT03470922 |
| relatlimab+nivolumab | 1 | — | — | NCT06101134 |
| Rituximab | 1 | 1 | Jan 2028 est. | NCT07015242 |
Phase 134 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| AG-120 | 1 | — | — | NCT02677922 |
| BMS-985521 | 1 | 1 | Nov 2026 est. | NCT07283263 |
| BMS-986158 | 1 | — | Aug 2028 est. | NCT04817007 |
| BMS-986340 | 1 | 1 | Aug 2031 est. | NCT04895709 |
| BMS-986449 | 1 | — | Sept 2026 est. | NCT05888831 |
| BMS-986453 | 1 | 1 | May 2030 est. | NCT06153251 |
| BMS-986454 | 1 | 1 | Jun 2027 est. | NCT07171983 |
| BMS-986458 | 1 | 1 | Oct 2027 est. | NCT06090539 |
| BMS-986460 | 1 | 1 | Aug 2029 est. | NCT06067841 |
| BMS-986463 | 1 | 1 | Dec 2028 est. | NCT06476808 |
| BMS-986470 | 1 | 1 | Jan 2027 est. | NCT06481306 |
| BMS-986482 | 1 | 1 | Jan 2029 est. | NCT06697197 |
| BMS-986484 | 1 | — | Oct 2027 est. | NCT06544655 |
| BMS-986488 | 1 | 1 | Oct 2027 est. | NCT06764771 |
| BMS-986489 | 1 | — | May 2027 est. | NCT06799286 |
| BMS-986490 | 1 | — | — | NCT06730750 |
| BMS-986497 | 1 | 1 | Feb 2027 est. | NCT06419634 |
| BMS-986500 | 1 | 1 | Dec 2028 est. | NCT06997029 |
| BMS-986506 | 1 | 1 | May 2030 est. | NCT07195682 |
| BMS-986517 | 1 | 1 | Jul 2028 est. | NCT07160725 |
| BMS-986521 | 1 | 1 | Dec 2026 est. | NCT07655518 |
| BMS-986523 | 1 | 1 | Oct 2028 est. | NCT07223047 |
| BMS-986525 | 1 | 1 | Apr 2029 est. | NCT07325136 |
| BMS-986528 | 1 | 1 | Oct 2029 est. | NCT07412704 |
| BMS-986533 | 1 | 1 | Jun 2027 est. | NCT07629999 |
| CC-122 | 1 | — | Oct 2026 est. | NCT05688475 |
| Elranatamab | 1 | 1 | May 2027 est. | NCT06988488 |
| elzovantinib (TPX-0022) | 1 | — | — | NCT03993873 |
| Fedratinib | 1 | — | — | NCT04446650 |
| JCAR017 (lisocabtagene maraleucel) | 1 | — | Nov 2027 est. | NCT03331198 |
| RYZ211/212 | 1 | — | Jul 2027 est. | NCT07671092 |
| RYZ401 | 1 | 1 | Feb 2027 est. | NCT07165132 |
| RYZ512 | 1 | — | Dec 2026 est. | NCT07671417 |
| RYZ801 | 1 | 1 | Jun 2030 est. | NCT06726161 |
Phase 46 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| DeucravacitinibBMS-986165 | 22 | 11 | Oct 2026 est. | NCT06875960 · NCT07791199 · NCT07116967 |
| Xanomeline/Trospium Chloride | 17 | 15 | Nov 2026 est. | NCT07221877 · NCT07288567 · NCT07285798 |
| Mavacamten | 12 | 8 | Nov 2026 est. | NCT07004972 · NCT06112743 · NCT06253221 |
| LuspaterceptACE-536 | 10 | 2 | Jul 2027 est. | NCT05891249 · NCT06045689 · NCT05949684 |
| OzanimodBMS-986374 | 4 | 3 | Dec 2028 est. | NCT06396039 · NCT06408259 · NCT05076175 |
| Nivolumab + Relatlimab | 2 | — | May 2029 est. | NCT07459543 · NCT05625399 |
Combination backbones Dexamethasone (1 trial). Established agents these trials combine with, listed separately from the drugs under study.
Derived from 218 active trials Bristol Myers Squibb leads; 213 name an intervention, folding into 71 phased drugs. 11 interventions carry no registry phase (observational studies, tests and devices) and are not shown. This is ComplyRx's reading of the registry, not Bristol Myers Squibb's own pipeline disclosure.
Bristol Myers Squibb trials
The 50 most significant of Bristol Myers Squibb's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsNCT04094610Oral repotrectinib (TPX-0005) | Phase 1 | Locked · track to reveal | OngoingRecruiting | 75 est. | 30 Sept 2026 |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)NCT05511363KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 410 est. | 5 Oct 2026 |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)NCT05853575Adagrasib | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 200 est. | 30 Oct 2026 |
| BALSAM-1A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderNCT06951698KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 274 est. | 1 Nov 2026 |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)NCT06951711KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 274 est. | 2 Nov 2026 |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)NCT06585787KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 406 est. | 24 Nov 2026 |
| A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female ParticipantsNCT07777133Navlimetostat | Phase 1 | Not yet scored | OngoingNot yet recruiting | 6 est. | 5 Dec 2026 |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)NCT06126224KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 500 est. | 9 Dec 2026 |
| A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionNCT07763418Golcadomide | Phase 1 | Not yet scored | OngoingNot yet recruiting | 30 est. | 14 Dec 2026 |
| A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult ParticipantsNCT07226817BMS-986435 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 240 est. | 17 Dec 2026 |
| A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseNCT06481306BMS-986470 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 224 est. | 6 Jan 2027 |
| SUCCESSOR-1A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)NCT05519085mezigdomide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 810 est. | 10 Jan 2027 |
| Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.NCT07165132RYZ401 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 104 est. | Feb 2027 |
| A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy ParticipantsNCT07800897Navlimetostat | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 80 est. | 25 Mar 2027 |
| A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending DosesNCT07063342Xanomeline/Trospium Chloride Capsule | Phase 1 | Locked · track to reveal | OngoingRecruiting | 236 est. | 29 Mar 2027 |
| MSSA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityNCT06782490BMS-986368 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | 26 May 2027 |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaNCT06988488Elranatamab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 62 est. | 31 May 2027 |
| A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose AdministrationNCT07780383BMS-986446 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 84 est. | 17 Jun 2027 |
| A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTNCT07061288KarXT | Phase 1 | Locked · track to reveal | OngoingRecruiting | 131 est. | 21 Jun 2027 |
| A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaNCT05664737Luspatercept | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 189 est. | 16 Jul 2027 |
| rechARgeA Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485BMS-986365 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 960 est. | 12 Sept 2027 |
| Long-Term Real-World Safety of Cobenfy in Adults With SchizophreniaNCT07783373xanomeline-trospium chloride | — | Locked · track to reveal | OngoingActive, not recruiting | 3,000 est. | 26 Sept 2027 |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasNCT06090539BMS-986458 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 460 est. | 28 Oct 2027 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseNCT06808984BMS-986368 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 120 est. | 26 Nov 2027 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionNCT05245500MRTX1719 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 336 est. | 10 Dec 2027 |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)NCT06615479BMS-986393 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 440 est. | 30 Dec 2027 |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaNCT07015242Rituximab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 65 est. | 9 Jan 2028 |
| A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132NCT06875960BMS-986165 | Phase 4 | Locked · track to reveal | OngoingRecruiting | 35 est. | 31 Jan 2028 |
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesNCT07415031Adagrasib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 170 est. | 16 Feb 2028 |
| BENCHMARK-SLEA Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 ImmunosuppressantsNCT07175285Current standard of care treatment options | — | Not yet scored | OngoingRecruiting | 223 est. | 24 Mar 2028 |
| A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276BMS-986489 (Atigotatug+Nivolumab) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 530 est. | 6 Apr 2028 |
| A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)NCT06929273KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 450 est. | 13 Jun 2028 |
| Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)NCT07379827Xanomeline and trospium chloride (KarXT) | — | Locked · track to reveal | OngoingRecruiting | 1,500 est. | 20 Jun 2028 |
| A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid TumorsNCT07160725BMS-986517 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 540 est. | 31 Jul 2028 |
| A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680BMS-986504 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 260 est. | 15 Aug 2028 |
| MINDSET 1A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseNCT06976216KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 586 est. | 11 Sept 2028 |
| MINDSET 2A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)NCT06976203KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 586 est. | 11 Sept 2028 |
| A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764Pumitamig | Phase 2 | Not yet scored | OngoingRecruiting | 160 est. | 15 Sept 2028 |
| TRACY-1Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.NCT06590857RYZ101 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 16 est. | Oct 2028 |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596Adagrasib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 626 est. | 31 Oct 2028 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseNCT07011745Xanomeline/Trospium Chloride Capsule | Phase 3 | Locked · track to reveal | OngoingRecruiting | 426 est. | 3 Nov 2028 |
| A Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderNCT07772531BMS-986511 | Phase 2 | Not yet scored | OngoingNot yet recruiting | 200 est. | 6 Nov 2028 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)NCT07011732Xanomeline/Trospium Chloride Capsule | Phase 3 | Locked · track to reveal | OngoingRecruiting | 426 est. | 24 Nov 2028 |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080Iza-bren | Phase 2 | Locked · track to reveal | OngoingRecruiting | 500 est. | 15 Dec 2028 |
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in IndiaNCT05891249Luspatercept | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 85 est. | 16 Dec 2028 |
| A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisNCT04772079Deucravacitinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 153 est. | 1 Jan 2029 |
| Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)NCT07101094xanomeline and trospium chloride (X/T) therapy | — | Locked · track to reveal | OngoingRecruiting | 300 est. | 31 Jan 2029 |
| Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaNCT07686263Xanomeline/Trospium Chloride | Phase 3 | Locked · track to reveal | OngoingRecruiting | 472 est. | 3 Mar 2029 |
| A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerNCT07325136BMS-986525 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 240 est. | 23 Apr 2029 |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNCT07459543Nivolumab + Relatlimab | Phase 4 | Locked · track to reveal | OngoingNot yet recruiting | 40 est. | 26 May 2029 |